Currently, CSF p-tau181, Aβ42/40, and total tau are used to diagnose AD in clinical practice.1 P-tau217 has recently gained attention due to its high sensitivity and specificity for AD, which are both slightly higher than p-tau181. In plasma, generally speaking, the diagnostic performance of most biomarkers is lower due to difficulties in measuring very low concentrations of abnormal proteins that are present in the blood. The exception is plasma p-tau217, which has excellent diagnostic performance in plasma.2,3 In fact, plasma p-tau217 has statistically non-distinguishable performance from currently used CSF biomarkers. Therefore, plasma p-tau217 will likely have an important role in the future clinical diagnosis of Alzheimer’s disease.2,3
Related content
Social and physical exposome factors—like poverty, pollution, and inequality—accumulate over time, shaping biological aging and cognitive decline. Through inflammation and cellular stress, these exposures drive neurodegeneration, highlighting the need for longitudinal, integrative research.
The exposome reframes dementia as the product of cumulative physical and social exposures-like pollution, nutrition, and inequality-across life. These factors shape brain aging through inflammation and epigenetic change. Lifespan, global studies are key to equitable dementia prevention.
